SCHEMBL11028071

SCHEMBL11028071

Cc1cc2c(cc1N)C(=O)NC2=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATAD2 Q6PL18 1/20 0.45
CYP3A4 P08684 2/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
BCHE P06276 1/20 0.41
CES1 P23141 1/20 0.41
GSK3B P49841 2/20 0.41
CDK4 P11802 1/20 0.41
CCNA2 P20248 1/20 0.41
CCND1 P24385 1/20 0.41
CDK2 P24941 1/20 0.41
CCNA1 P78396 1/20 0.41
ALDH1A1 P00352 3/20 0.40
MAPT P10636 2/20 0.40
HTT P42858 2/20 0.40
EGFR P00533 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7278521 0.83 GSK3B (0.47) CYP3A4MAPK1BCHECES1GSK3B
SCHEMBL441276 0.83 PPOX (0.46) CYP3A4MAPK1GSK3BALDH1A1MAPT
SCHEMBL22158492 0.77 ATAD2 (0.45) ATAD2CYP3A4TSHRMAPK1ALDH1A1
SCHEMBL1424404 0.77 GSK3B (0.40) CYP3A4MAPK1BCHECES1GSK3B
SCHEMBL23172302 0.74 GRM5 (0.43) CYP3A4MAPK1BCHECES1GSK3B
SCHEMBL3872555 0.74 GRM5 (0.43) CYP3A4MAPK1GSK3BALDH1A1MAPT
SCHEMBL24414145 0.73 PPOX (0.39) CYP3A4MAPK1GSK3BALDH1A1MAPT
SCHEMBL11057362 0.73 PPOX (0.48) BCHECES1GSK3BCDK4CCNA2
SCHEMBL24414673 0.73 KDM4E (0.52) CYP3A4MAPK1BCHECES1GSK3B
SCHEMBL30991840 0.73 PPOX (0.39) CYP3A4MAPK1GSK3BALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113474340-B Novel isoindolinone substituted indoles and derivatives as RAS inhibitors 勃林格殷格翰国际有限公司 2024-07-23 CN disclosed
EP-3931188-B1 NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2023-08-30 EP disclosed
US-20220144810-A1 NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-05-12 US disclosed
WO-2017049409-A1 COMPOSITIONS FOR PROMOTING READTHROUGH OF PREMATURE TERMINATION CODONS, AND METHODS OF USING THE SAME THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) 2017-03-30 WO disclosed
EP-0064952-B1 MONOAZO DYESTUFFS CIBA-GEIGY AG (CH) 1985-07-24 EP disclosed
US-4473500-A Monoazo pigments derived from aminophthalimides and substituted acetoacetarylides or 2-hydroxy-3-naphthoylarylides CIBA-GEIGY CORPORATION (US) 1984-09-25 US disclosed
EP-0064952-A1 Monoazo dyestuffs CIBA-GEIGY AG (CH) 1982-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144810-A1 NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS NRAS, RASSF5, KRAS ATAD2 1820/4885CYP3A4 2682/4885TSHR 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.